421 related articles for article (PubMed ID: 9563008)
1. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
Song K; Li Z; Seth P; Cowan KH; Sinha BK
Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
[TBL] [Abstract][Full Text] [Related]
2. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
Song K; Cowan KH; Sinha BK
Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
[TBL] [Abstract][Full Text] [Related]
3. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
4. Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells.
Arah IN; Song K; Seth P; Cowan KH; Sinha BK
Anticancer Res; 1998; 18(3A):1845-9. PubMed ID: 9673414
[TBL] [Abstract][Full Text] [Related]
5. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma.
Herod JJ; Eliopoulos AG; Warwick J; Niedobitek G; Young LS; Kerr DJ
Cancer Res; 1996 May; 56(9):2178-84. PubMed ID: 8616869
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.
Jones NA; Turner J; McIlwrath AJ; Brown R; Dive C
Mol Pharmacol; 1998 May; 53(5):819-26. PubMed ID: 9584207
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells.
Katayose D; Gudas J; Nguyen H; Srivastava S; Cowan KH; Seth P
Clin Cancer Res; 1995 Aug; 1(8):889-97. PubMed ID: 9816059
[TBL] [Abstract][Full Text] [Related]
12. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
Ramirez PT; Gershenson DM; Tortolero-Luna G; Ramondetta LM; Fightmaster D; Wharton JT; Wolf JK
Gynecol Oncol; 2001 Dec; 83(3):543-8. PubMed ID: 11733969
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
Ramondetta L; Mills GB; Burke TW; Wolf JK
Clin Cancer Res; 2000 Jan; 6(1):278-84. PubMed ID: 10656459
[TBL] [Abstract][Full Text] [Related]
14. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.
Debernardis D; Siré EG; De Feudis P; Vikhanskaya F; Valenti M; Russo P; Parodi S; D'Incalci M; Broggini M
Cancer Res; 1997 Mar; 57(5):870-4. PubMed ID: 9041188
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of growth-inhibitory effect of cisplatin on human pancreatic cancer cells and status of p53 gene.
Seki T; Ohba N; Makino R; Funatomi H; Mitamura K
Anticancer Res; 2001; 21(3B):1919-24. PubMed ID: 11497278
[TBL] [Abstract][Full Text] [Related]
16. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.
Eliopoulos AG; Kerr DJ; Herod J; Hodgkins L; Krajewski S; Reed JC; Young LS
Oncogene; 1995 Oct; 11(7):1217-28. PubMed ID: 7478541
[TBL] [Abstract][Full Text] [Related]
17. Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II).
Husain A; Rosales N; Schwartz GK; Spriggs DR
Gynecol Oncol; 1998 Jul; 70(1):17-22. PubMed ID: 9698467
[TBL] [Abstract][Full Text] [Related]
18. A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: a gene therapy approach for drug-resistant cancers.
Seth P; Katayose D; Li Z; Kim M; Wersto R; Craig C; Shanmugam N; Ohri E; Mudahar B; Rakkar AN; Kodali P; Cowan K
Cancer Gene Ther; 1997; 4(6):383-90. PubMed ID: 9408609
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
20. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
Kigawa J; Sato S; Shimada M; Kanamori Y; Itamochi H; Terakawa N
Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]